<DOC>
	<DOCNO>NCT01003808</DOCNO>
	<brief_summary>The purpose study determine biological recommend dose IMF-001 .</brief_summary>
	<brief_title>Safety Study Recombinant Protein Vaccine Treat Esophageal Cancer</brief_title>
	<detailed_description>The prognosis esophageal cancer improve improvement surgery , chemotherapy radiation therapy . However , standard therapy establish recurrent esophageal cancer . NY-ESO-1 antigen express 33 % patient . NY-ESO-1 protein applicable without limitation HLA type , inject complex cholesteryl pullulan ( CHP ) , form nano-particles ( IMF-001 ) , activate CD4+ CD8+ T cell . In phase 1 study , safety biological recommend dose determine .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<criteria>Radically unresectable stage III/IV esophageal tumor fail standard treatment ( include chemotherapy radiotherapy ) , recurrent metastasis radical surgery respond standard treatment , recurrent metastasis radiotherapy before/after radical surgery . Primary esophageal tumor confirm pathological diagnosis Tumor cell express NYESO1 antigen ( tissueimmunostaining method quantitative RTPCR method ) Performance status ( PS ) 0 , 1 2 ( ECOG Scale ) Life expectancy &gt; /= 4 month No serious disorder major organ ( bone marrow , heart , lung , liver kidney ) meet follow criterion : WBC count &gt; /= 2.0 x 10 9/L Hemoglobin &gt; /=8.0g/dL Platelet count &gt; /=75 x 10 9/L Serum total bilirubin : &lt; /=1.5 x ULN ( 3 x ULN liver mets ) AST ALT : &lt; /=2.5 x ULN ( 5x ULN liver mets ) Serum creatinine : &lt; /=1.5x ULN Agree use birth control include condom time obtain consent 6 month final administration study drug [ except female menopause ( 1 year last menstruation females/males operation sterilization ) ] Given write informed consent HIV antibody positive Double cancer History autoimmune disease History severe anaphylaxis Active metastatic disease central nervous system ( CNS ) Within 4 week treatment antitumor agent , systemically administer adrenocorticosteroids , immune suppressant immune enhancer Pregnant lactate Any inadequacy study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>